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TRANSLATIONAL PHYSIOLOGY
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Neglia D, De Caterina A, Marraccini P, Natali A, Ciardetti M,
Vecoli C, Gastaldelli A, Ciociaro D, Pellegrini P, Testa R,
Menichetti L, L’Abbate A, Stanley WC, Recchia FA. Impaired
myocardial metabolic reserve and substrate selection flexibility during
stress in patients with idiopathic dilated cardiomyopathy. Am J
Physiol Heart Circ Physiol 293: H3270–H3278, 2007. First published
October 5, 2007; doi:10.1152/ajpheart.00887.2007.—Under resting
conditions, the failing heart shifts fuel use toward greater glucose and
lower free fatty acid (FFA) oxidation. We hypothesized that chronic
metabolic abnormalities in patients with dilated cardiomyopathy
(DCM) are associated with the absence of the normal increase in
myocardial glucose uptake and maintenance of cardiac mechanical
efficiency in response to pacing stress. In 10 DCM patients and 6
control subjects, we measured coronary flow by intravascular ultra-
sonometry and sampled arterial and coronary sinus blood. Myocardial
metabolism was determined at baseline, during atrial pacing at 130
beats/min, and at 15 min of recovery by infusion of [3H]oleate and
[13C]lactate and measurement of transmyocardial arteriovenous dif-
ferences of oxygen and metabolites. At baseline, DCM patients
showed depressed coronary flow, reduced uptake and oxidation of
FFA, and preferential utilization of carbohydrates. During pacing,
glucose uptake increased by 106% in control subjects but did not
change from baseline in DCM patients. Lactate release increased by
122% in DCM patients but not in control subjects. Cardiac mechanical
efficiency in DCM patients was not different compared with control
subjects at baseline but was 34% lower during stress. Fatty acid
uptake and oxidation did not change with pacing in either group. Our
results show that in DCM there is preferential utilization of carbohy-
drates, which is associated with reduced flow and oxygen consump-
tion at rest and an impaired ability to increase glucose uptake during
stress. These metabolic abnormalities might contribute to progressive
cardiac deterioration and represent a target for therapeutic strategies
aimed at modulating cardiac substrate utilization.
microcirculation
FATTY ACIDS provide 60–90% of the energy necessary to sustain
contractile function in the resting fasting state, with the re-
mainder coming from glucose and lactate oxidation. During
acute cardiac stress, such as pacing or exercise, the healthy
human heart rapidly increases glucose and lactate uptake, with
a relative decline in free fatty acid (FFA) uptake (1, 3, 4, 9).
Clinical and animal studies have suggested that this response is
advantageous: it increases myocardial metabolic efficiency,
since carbohydrates are a more efficient substrate than lipids,
generating more contractile power for any given rate of myo-
cardial oxygen consumption (MV˙ O2) (20, 29, 31).
Dilated cardiomyopathy (DCM) is often characterized by
reduced FFA uptake and oxidation and accelerated glycol-
ysis and glucose oxidation under resting conditions (7, 21,
31). This metabolic shift may act to optimize the limited
oxidative capacity of cardiomyopathic hearts resulting from
impairment of mitochondrial function (28) and/or ATP
transfer from mitochondria to the contractile apparatus (30)
or reduced myocardial perfusion and flow reserve due to
coronary microvascular dysfunction (16, 17). Little is
known about myocardial metabolism in DCM patient under
conditions of increased workload. Factors that differentiate
DCM from healthy conditions (altered metabolic phenotype,
limited oxidative capabilities, reduced flow availability,
etc.) might limit the ability of the dysfunctional myocardium
to adapt to acute stress. The myocardial metabolic and flow
response to acute atrial pacing stress has been extensively
investigated in patients with syndrome X (1, 3) and coronary
artery disease (23, 24, 39) but not in DCM patients. This
information is clinically relevant, since metabolic modula-
tors, such as agents that partially inhibit myocardial FFA
oxidation, improve symptoms of stress-induced ischemia in
angina patients (32) and ventricular function in patients with
ischemic cardiomyopathy (2, 13, 31, 37), but the rationale
for their potential use in heart failure and DCM is still under
debate.
The purpose of the present investigation was to assess the
relationships among cardiac substrate metabolism, ventricular
dysfunction, and coronary blood flow (CBF) at rest and in
response to acute pacing stress in DCM patients and in a
control group of patients with normal coronary arteries and left
ventricular (LV) mass and volume. We hypothesized that the
chronic metabolic abnormalities in DCM observed at rest are
associated with the absence of the normal response to pacing
stress, namely, an increase in myocardial glucose uptake and
maintenance of cardiac mechanical efficiency. Coronary he-
modynamics and myocardial substrate metabolism were mea-
sured directly by cardiac catheterization and transmyocardial
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blood sampling using an infusion of [3H]oleate and [13C]lac-
tate tracers.
MATERIALS AND METHODS
Study Population
From October 2003 to May 2006, we enrolled 10 consecutive
patients with DCM and 6 patients with normal LV function (controls),
which were selected among the 329 patients admitted to the cardiol-
ogy unit of the Institute of Clinical Physiology in Pisa, Italy, and
showed normal coronary arteries with angiography. DCM patients
were selected according to the following inclusion criteria: age be-
tween 20 and 80 yr, LV ejection fraction (EF) 40%, LV end-
diastolic diameter (LVEDD) 56 mm, and angiographically normal
coronary arteries (50% coronary diameter stenosis). Exclusion cri-
teria were as follows: New York Heart Association (NYHA) class IV,
previous myocardial infarction, valvular heart disease, actual systemic
arterial hypertension, myocardial active inflammatory/infective dis-
eases (such as myocarditis or pericarditis), current cigarette smoking,
diabetes, or the presence of other systemic illnesses (such as neopla-
sia, renal, hepatic, or respiratory failure or atrial fibrillation). Control
patients underwent coronary angiography for history of angina-like
chest pain and/or previous stress tests suspicious for myocardial
ischemia. Inclusion criteria for control patients were as follows: age
between 20 and 80 yr, LV EF50%, LVEDD56 mm, angiographi-
cally normal coronary arteries (50% coronary diameter reduction),
and the absence of other cardiovascular or systemic diseases.
Both groups of patients underwent routine blood tests, ECG, chest
X-ray, and resting two-dimensional echocardiogram. LV function,
dimension, and mass were evaluated from two-dimensional echocar-
diogram data according to standardized protocols (12). Eight DCM
patients were also submitted, within 30 days after the catheterization
procedure, to PET with [13N]ammonia to measure the specific blood
flow per gram of myocardial tissue (ml min1 g1) at rest. Specific
flow was computed according to standardized protocols (17) in the left
anterior descending coronary artery (LAD) myocardial territory (5).
The study was approved by the local ethical committee and con-
formed to the Declaration of Helsinki on human research, and written
informed consent was obtained on the day before cardiac catheteriza-
tion after complete explanation of the protocol and potential risks. All
coronary-active drugs, including nitrates, Ca2 antagonists, -block-
ers, angiotensin-converting enzyme inhibitors, or statins, were sus-
pended at least 24 h before catheterization.
Cardiac Catheterization
In the morning, after an overnight fast, all patients were submitted
to routine coronary angiography and definitively enrolled after ex-
cluding the presence of significant coronary stenosis.
Cardiac catheterization was performed to measure coronary perfu-
sion pressure, flow velocity, and cross-sectional area in the proximal
third of the LAD and transmyocardial arteriovenous gradients across
the LAD myocardial territory of labeled ([L-3-13C]lactate and
[9,10-3H]oleate) and nonlabeled substrates (FFA, glucose, and lac-
tate). At the completion of diagnostic catheterization, an intravenous
bolus of 110 mg [L-3-13C]lactate was administered, followed by an
intravenous continuous infusion of [9,10-3H]oleate at 84 Ci/h and
[L-3-13C]lactate at 130 mg/h, allowing a 30-min equilibration period.
The [13C]lactate tracer was used to measure the simultaneous lactate
uptake and efflux from the myocardium (8, 9, 39), and the [3H]oleate
tracer was used to measure FFA oxidation from the myocardial
production of 3H2O (21). A 6-Fr guiding catheter was placed in the
left main coronary ostium through a 7-Fr femoral artery introducer.
An intracoronary heparin bolus (100 U/Kg) was given, and a 0.014-in.
Doppler flow wire (FloWire, Volcano) was advanced into the LAD. A
2.9-Fr, 10-MHz intravascular ultrasound (IVUS) catheter (Eagle Eye
Gold, Volcano) was passed over the flow wire and positioned in the
LAD coronary artery immediately distal to the first septal perforating
branch. The Doppler flow wire was positioned 2 cm distal to the tip
of the IVUS catheter to avoid artifacts caused by the catheter wake.
The positions of the IVUS catheter and flow wire were documented by
angiography and maintained throughout the study by fluoroscopic
control. After LAD instrumentation, a 5-Fr catheter was advanced into
the coronary sinus, up to the great cardiac vein, to withdraw venous
blood from the LAD territory, and a unipolar pacing catheter was then
positioned into the right atrium. Due to the complexity of the instru-
mentation, five additional patients, fulfilling the inclusion criteria but
in whom the catheterization procedures could not be completed, were
excluded from the study.
After calibration, phasic and mean coronary perfusion pressure
(from the guiding catheter) and coronary flow velocity signals were
continuously recorded on paper and acquired, together with ECG
(leads DI-DII-DIII), on a personal computer equipped with dedicated
software. IVUS images were obtained for 30 s at each step of the
protocol, with temporal synchronization with flow velocity signals,
and recorded for off-line analysis.
At each step of the protocol, arterial and venous blood samples
were withdrawn simultaneously, over 30 s, from the femoral artery
introducer and great cardiac vein and immediately processed for gas
analysis and measurements of metabolite concentrations.
Study Protocol
The study protocol consisted of four steps. After the instrumenta-
tion was completed (30 min), continuous monitoring of coronary
hemodynamic signals was started and the baseline arteriovenous
sampling was performed (“Baseline”). Heart rate was increased by
atrial pacing to 110 beats/min for 3 min and to 130 beats/min for 3
additional min, and arteriovenous sampling was repeated (“Pacing”).
Pacing was then stopped, and, 15 min later, a third pair of arterio-
venous samples was withdrawn (“Recovery”). After an additional 15
min, when all hemodynamic parameters had returned to baseline, an
intravenous adenosine infusion was given for 3 min unless it was not
clinically tolerated or significant bradycardia (HR  50 beats/min) or
hypotension (systolic pressure  90 mmHg) occurred. Coronary
parameters were acquired at the end of the third minute of adenosine
administration, or just before suspension, and were used to estimate
coronary flow reserve.
Data Analysis
Coronary flow. Coronary flow was calculated offline by multiply-
ing Doppler-derived mean flow velocity by coronary lumen cross-
sectional area as measured by IVUS as described in the Data
Supplement.1
Coronary flow reserve was computed as adenosine/resting CBF. An
estimate of myocardial mechanical efficiency was obtained from the
rate-pressure product (RPP) and MV˙ O2 measured at each step as
follows (see also the Data Supplement):
(RPP/LV mass)/[MV˙ O2/(0.54 LV mass)]	 (RPP 0.54)/MV˙ O2.
Metabolites. Blood samples from the femoral artery and coronary
sinus were withdrawn slowly to avoid hemolysis and potential con-
tamination with right atrial blood. The first 5 ml from the coronary
sinus catheter were discarded to avoid contamination from either
saline or blood present in the catheter. Oxygen consumption and
metabolite uptake and oxidation were measured as previously de-
scribed (9, 10, 26) (see Data Supplement). The percent MV˙ O2 due to
FFA or lactate oxidation was calculated as previously described (26).
For lactate, it was assumed that 100% of the [13C]lactate taken up by
the heart was oxidized to CO2 (9).
1 Supplemental material for this article is available online at the American
Journal of Physiology-Heart and Circulatory Physiology website.
H3271ABNORMAL METABOLISM IN DILATED CARDIOMYOPATHY
AJP-Heart Circ Physiol • VOL 293 • DECEMBER 2007 • www.ajpheart.org
 o
n
 April 18, 2012
ajpheart.physiology.org
D
ow
nloaded from
 
Statistics. Data are presented as means 
 SE. Differences among
patient groups for discrete clinical variables were evaluated by 2-test.
Coronary hemodynamic and metabolic data were compared in each
study condition among groups and for different study conditions in the
same group by two-way ANOVA followed by Fisher’s exact test. An
unpaired t-test was used to compare single study conditions between
groups when appropriate. P values of 0.05 were considered
significant.
RESULTS
Characteristics of the Study Population
Clinical, functional, and biohumoral data are shown in Table
1. The two groups did not significantly differ in age or sex.
History of angina-like chest pain was more frequent in con-
trols, whereas risk factors were similar in the two groups. Body
mass index and the ratio of total triglycerides over HDL-
cholesterol (surrogate measures of insulin resistance and met-
abolic syndrome) did not differ between the two groups. DCM
patients showed reduced LV systolic function and an enlarged
LV chamber, frequent left bundle branch block, and higher
brain natriuretic peptide (BNP) and NH2-terminal pro-BNP
plasma levels. However, DCM patients did not show evidence
of advanced heart failure (8 of 10 patients in NYHA classes I
and II) or extensive sympathetic activation (norepinephrine
plasma levels were not significantly different between DCM patients and controls). Use of primary cardioactive drugs was
not significantly different between the two groups except for
digoxin and diuretics in DCM patients.
Coronary Hemodynamics
In one patient in the control group, the coronary sinus
catheter was displaced into the right atrium; thus, metabolic
measurements were not obtained. In two patients of the DCM
group, the pacing rate was maintained at 110 beats/min since
they did not tolerate higher rates; in one of these two patients
and in one other patient, intravenous adenosine was not ad-
ministered as they asked to shorten the study.
Data on coronary hemodynamics during and after pacing
stress are shown in Table 2. While heart rates were not
significantly different between controls and DCM patients,
coronary mean perfusion pressure, RPP, and CBF in the LAD
territory were lower in DCM patients than in controls under all
the study conditions. From baseline to pacing, heart rates and
RPP significantly increased in both groups and were restored to
baseline levels at recovery. CBF significantly increased during
pacing only in the DCM group and significantly decreased at
recovery in the control group.
During intravenous adenosine infusion, there was a trend for
CBF to remain lower in DCM patients than in controls (2.18

1.30 vs 3.29 
 0.89 ml min1 g1, P 	 0.09), whereas the
coronary flow reserve was not significantly different between
the two groups (3.59 
 2.53 vs 3.31 
 1.25, not significant).
Myocardial Metabolism and Energetics
Baseline arterial concentrations of the major cardiac sub-
strates were not significantly different between the two groups
(Table 3) and did not significantly change during the study.
DCM patients showed significantly lower FFA uptake and
oxidation at all time points and significantly higher glucose
uptake than controls at baseline (Fig. 1). During pacing, glu-
cose uptake significantly increased in controls by 106% but did
Table 1. Clinical, functional, and biohumoral data
Controls
DCM
Patients P Values
Subject characteristics
n 6 10
Age, yr 67
2 57
3 NS
Males 3 (30) 7 (70) NS
Angina 5 (83) 2 (20) 0.05
Left branch bundle block 2 (33) 9 (90) 0.05
LV mass, g 164
11 287
19 0.01
New York Heart Association class
III 0 2 (20) NS
Functional data
LV EF, % 58
1 32
1 0.001
LVEDD, mm 49
1 65
1 0.001
Neurohormonal data
BNP, pg/ml 21
7 91
22 0.05
NH2-terminal pro-BNP, pg/ml 123
37 593
130 0.05
Norepinephrine, pg/ml 210
54 412
81 NS
Risk factors
Body mass index, kg/m2 28
2 29
2 NS
Fasting glycemia, mg/dl 90
4 101
9 NS
Total triglycerides/HDL-cholesterol 2.79
1.73 3.07
2.71 NS
HDL/total cholesterol 0.23
0.02 0.24
0.02 NS
Treatment
Statins 3 (50) 3 (30) NS
Antiplatelet 2 (33) 5 (50) NS
Ca2 antagonists 1 (17) 0 NS
-Blockers (carvedilol) 3 (50) 6 (60) NS
Angiotensin-converting enzyme
inhibitors/angiotensin type 1
receptor antagonists 3 (50) 9 (90) NS
Antialdosteronics 0 3 (30) NS
Diuretics 1 (17) 8 (80) 0.05
Digoxin 0 5 (50) 0.05
Values are means 
 SE and are numbers of subjects (n) with percentages in
parentheses unless otherwise stated. DCM, dilated cardiomyopathy; LV, left
ventricular; EF, ejection fraction; LVEDD, LV end-diastolic diameter; BNP,
brain natriuretic peptide; NS, not significant.
Table 2. Hemodynamics
Controls DCM Patients
Heart rate, beats/min
Baseline 75
5 71
4a
Pacing 132
4e 124
4a,e
Recovery 77
7 71
4a
Mean aortic pressure, mmHg
Baseline 107
2 89
3b
Pacing 109
3c 91
4b,c
Recovery 105
4 90
4b
Rate-pressure product,
mmHg  beats  min1
Baseline 8,086
590 6,320
413b
Pacing 14,475
642e 11,314
647b,e
Recovery 8,155
870 6,438
440b
Left anterior descending coronary artery
CBF, ml  min1  g1
Baseline 1.08
0.07 0.66
0.06b
Pacing 1.19
0.07c 0.91
0.07b,d
Recovery 0.84
0.04f 0.64
0.07b
Values are means
 SE. CBF, coronary blood flow. aP	 NS, DCM patients
vs. controls; bP  0.001, DCM patients vs. controls; cP 	 NS, pacing vs.
baseline and recovery; dP  0.01, pacing vs. baseline and recovery; eP 
0.001, pacing vs. baseline and recovery; fP  0.05, recovery vs. baseline and
pacing.
H3272 ABNORMAL METABOLISM IN DILATED CARDIOMYOPATHY
AJP-Heart Circ Physiol • VOL 293 • DECEMBER 2007 • www.ajpheart.org
 o
n
 April 18, 2012
ajpheart.physiology.org
D
ow
nloaded from
 
not change in DCM patients, so that it was no longer different
between the two groups. The percent net extraction of arterial
FFA was unaffected by pacing and was similar between groups
(Table 4). On the other hand, glucose and lactate extraction
were higher in the DCM group than in the control group.
Glucose extraction did not significantly increase during pacing
stress in controls but decreased significantly in DCM patients
compared with baseline and recovery periods (Table 4).
The tracer-measured myocardial uptake of lactate was not
significantly different between controls and DCM patients at
baseline and did not show significant changes during stress in
both groups (Fig. 2). At recovery, it significantly decreased in
controls. Myocardial lactate release was significantly lower
in DCM patients than in controls at baseline, but during pacing
it significantly increased by 122% in DCM patients and
reached levels similar to controls. Net uptake tended to be
higher in DCM patients, but this difference was not statistically
significant.
Overall, RPP and MV˙ O2 were lower in DCM patients than in
controls (Fig. 3). However, the ratio of RPP to MV˙ O2 (an index
of myocardial mechanical efficiency, i.e., work performed for
a given amount of oxygen consumed) was significantly lower
in DCM patients only during stress and at recovery. In fact,
during pacing, RPP increased in both groups, but MV˙ O2 in-
creased only in DCM patients. At recovery, RPP returned to
baseline in both groups, but in controls MV˙ O2 declined below
baseline levels. The analysis of the percent MV˙ O2 due to
oxidation of FFA showed that FFA contributed more to MV˙ O2
in controls than in DCM patients and that this difference was
attenuated during pacing stress (Fig. 4, top). While the contri-
bution of lactate oxidation to MV˙ O2 tended to be greater in
DCM patients than in controls, this difference did not reach
statistical significance (Fig. 4, bottom).
Correlations Between LV Remodeling and Metabolism,
Energetics, and CBF
There was a strong inverse correlation between LV diameter
(an index of LV dysfunction/remodeling) and CBF, MV˙ O2, and
FFA uptake in the whole study population under basal condi-
tions (Fig. 5). There was a nonsignificant trend toward a
positive correlation with glucose uptake (r 	 0.41, not signif-
icant). Both under resting conditions and during pacing, FFA
uptake (but not glucose uptake) was directly related with MV˙ O2
(Fig. 6).
DISCUSSION
This study provides direct evidence for a chronic cardiac
metabolic shift under both resting conditions and with pacing
stress in DCM patients without advanced heart failure. This
change in cardiac metabolic profile was characterized by de-
creased FFA uptake and oxidation and increased carbohydrate
utilization and was associated with reduced cardiac work,
MV˙ O2, and myocardial blood flow both at rest and in response
to stress. These results suggest the novel view that, while the
switch away from FFA oxidation in the failing heart is thought
to be compensatory under resting conditions, it may be detri-
mental during even moderate stress, potentially contributing to
the progressive deterioration of myocardial function.
Fig. 1. Cardiac free fatty acid (FFA) uptake (top), FFA oxidation (middle), and
glucose uptake (bottom) in controls (n 	 5) and DCM patients (n 	 10) at
baseline, during atrial pacing, and at recovery. *P  0.05, pacing vs. baseline
and recovery; #P  0.05, DCM patients vs. controls.
Table 3. Arterial concentration of substrates
Controls
DCM
Patients P Values
FFA 1.93
0.21 1.34
0.18 NS
Glucose 5.45
0.09 5.37
0.31 NS
Lactate 0.51
0.03 0.61
0.08 NS
Values are means 
 SE (in mol/ml). FFA, free fatty acids.
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Previous studies in patients with cardiomyopathy/heart fail-
ure have yielded conflicting results. Noninvasive PET studies
in nonischemic cardiomyopathy found reduced uptake and
oxidation of [11C]palmitate (35) and/or increased uptake and
utilization of [11C]glucose (7), consistent with our direct inva-
sive measurements. However, other PET studies, using FFA
and glucose analogs in ischemic and nonischemic patients with
advanced heart failure, found opposite results, with increased
lipids and decreased carbohydrate uptake (33, 38). Paolisso
et al. (22) evaluated myocardial energy metabolism in patients
with heart failure by direct invasive measurement of transmyo-
cardial substrate gradients and showed increased FFA utiliza-
tion. However, this study enrolled patients with NYHA class II
and III heart failure of ischemic and nonischemic origin and no
labeled substrates were used. In the present study, patients
were carefully selected to include only those with idiopathic
DCM and without advanced heart failure to avoid the potential
confounding effects of coronary disease and of systemic
metabolic derangement associated with cardiac decompensa-
tion. In severe heart failure, elevated adrenergic stimulation
may increase MV˙ O2 and levels of FFA, and cardiac insulin
resistance may develop (19). As a consequence, both fatty acid
and glucose utilization may be altered, and a condition of
energy imbalance may ensue, as recently discussed by
Neubauer (18).
The resting metabolic pattern that we found in DCM is
similar to that observed in the experimental model of pacing-
induced cardiomyopathy (21, 25) and is consistent with find-
ings in other animal models of progressive cardiac dysfunction
and heart failure (11). This shift in myocardial substrate
metabolism partially mimics the neonatal metabolic pheno-
type, with glucose and lactate instead of fatty acid being the
primary energy substrate (31). It remains to be determined
whether these alterations are a compensatory response of the
failing heart that optimizes cardiac energy metabolism and
prevents further deterioration of LV function or rather is a
maladaptation that contributes to the progression toward de-
compensation. Insight on this issue comes from mice with
cardiac-specific overexpression of insulin-independent glucose
transporter 1, which have increased glucose uptake and less
contractile dysfunction and LV dilation in response to chronic
pressure overload (15), suggesting that accelerated glucose
metabolism prevents hypertension-induced heart failure.
We observed an inverse correlation between cardiac FFA
metabolism and the extent of LV remodeling, which was also
associated with reduced MV˙ O2, myocardial blood flow, and
Fig. 2. Cardiac net lactate uptake (top) and tracer-measured lactate uptake
(middle) and release (bottom) in controls (n 	 5) and DCM patients (n 	 10)
at baseline, during atrial pacing, and at recovery. *P  0.05, pacing vs.
baseline and recovery; †P  0.05, recovery vs. baseline and pacing. #P 
0.05, DCM patients vs. controls.
Table 4. Percent transmyocardial net extraction of arterial
FFA, glucose, and lactate
Controls
DCM
Patients P Value
FFA extraction
Baseline 15
5 18
10 NS
Pacing 12
5 15
8 NS
Recovery 17
6 19
12 NS
Glucose extraction
Baseline 1
1 4
2† 0.05
Pacing 2
1 2
2*† NS
Recovery 1
1 5
7† NS
Lactate extraction
Baseline 18
14 32
11‡ NS
Pacing 17
12 27
11‡ NS
Recovery 9
8 29
16‡ 0.05
Values are means 
 SE (in %). P values are DCM patients versus controls
under the given conditions. *P  0.05 compared with baseline and recovery;
†P  0.05, DCM patients vs. control for main effect; ‡P  0.001, DCM
patients vs. controls for main effect.
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cardiac work. A primary depression of myocardial function, as
can be expected in DCM, could cause reduced energy require-
ments and MV˙ O2 and consequently reduced blood flow with
downregulation of FFA metabolism and a possible increase in
carbohydrate utilization. A reduction of myocardial oxygen
availability due to impaired myocardial perfusion and coronary
microvascular dysfunction (16, 17) and impaired oxygen uti-
lization consequent to mithocondrial dysfunction (28) have
been also described in DCM. These mechanisms reduce energy
transduction and further impair contractility and could, by
themselves, stimulate the myocardial metabolic shift from fat
oxidation to preferential utilization of carbohydrates. On the
other hand, a primary metabolic abnormality could exist, with
lower activity of the -oxidation pathway (27), lowering MV˙ O2
and causing metabolic downregulation of coronary flow, but
also energy depletion and reduced contractile function.
Myocardial Metabolic Response to Stress in DCM
The myocardial metabolic response to stress in DCM pa-
tients had not previously been investigated. It is well estab-
lished that in normal hearts, a high rate pacing induces a rapid
increase in glucose and lactate uptake coupled with a relative
decline in FFA uptake (1, 3, 4, 9). Clinical and experimental
studies have suggested that this response is advantageous,
since it increases myocardial mechanical efficiency as carbo-
hydrates are a more efficient substrate than lipids and provides
more energy for the generation of contractile power for any
given MV˙ O2 (20, 29, 31). The response to pacing stress in
Fig. 3. Rate-pressure product [RPP; in mmHg  beats  min1 (bpm); top], an
estimate of cardiac work, myocardial oxygen consumption (MV˙ O2; middle),
and mechanical efficiency, estimated from the ratio between RPP and MV˙ O2
(bottom), in controls (n 	 5) and DCM patients (n 	 10) at baseline, during
atrial pacing, and at recovery. All values were corrected for left ventricular
(LV) myocardial mass. *P  0.05, pacing vs. baseline and recovery; #P 
0.05, DCM patients vs. controls.
Fig. 4. Percent contribution of FFA oxidation (top) or lactate oxidation
(bottom) to MV˙ O2 in controls (n 	 5) and DCM patients (n 	 10) at baseline,
during atrial pacing, and at recovery. #P  0.05, DCM patients vs. controls.
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DCM patients was very different from the control group:
glucose uptake, which at baseline was already elevated in
DCM patients to levels similar to those reached in controls
during stress, did not further increase. In contrast, FFA utili-
zation tended to increase and the relative contribution of lipid
oxidation to MV˙ O2, which was clearly lower in DCM patients
than in controls under resting conditions, became similar be-
tween the two groups during stress. Compared with controls,
there was a lower increase in myocardial mechanical efficiency
during pacing in DCM patients. Taken together, these findings
strongly indicate that there is a more limited cardiac metabolic
reserve and flexibility in DCM. One of the possible mecha-
nisms explaining the metabolic rigidity of the failing heart is
the paradoxical downregulation of key enzymes of the carbo-
hydrate oxidative pathway, despite the higher glucose oxida-
tion, which we have previously described in dogs (14). As a
consequence, the cardiomyopathic heart must face even mod-
erate increases in cardiac work by oxidizing less efficient
substrates, such as FFA, which require higher oxygen con-
sumption and blood flow.
This abnormal metabolic behaviour, together with impaired
mitochondrial function (28) and limited myocardial flow and
oxygen availability, possibly due to coronary microvascular
dysfunction (16, 17), could contribute to an ischemic-like
condition (6, 36), enhanced oxidative stress, and energy deple-
tion in the cardiomyopathic heart.
Study Limitations
The small number of both DCM and control patients, due to
the strict selection criteria and the complexity of the protocol,
limits the statistical power. A second limitation is the lack of a
completely normal control population. Control patients had a
history of angina-like chest pain and/or stress testing sugges-
tive for ischemia. However, neither group of patients had the
typical clinical and ECG pattern of syndrome X nor developed
Fig. 5. Correlations between LV end-diastolic diameter (LVEDD) and resting
coronary blood flow (CBF; top), MV˙ O2 (middle), and myocardial FFA uptake
(bottom) in controls and DCM patients.
Fig. 6. Correlations between MV˙ O2 and myocardial FFA uptake (top) and
glucose uptake (bottom) measured at rest and during pacing in controls and
DCM patients.
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chest pain or significant S-T segment depression during pacing
stress. Since coronary catheterization procedures have an in-
trinsic risk to life, it is unethical to study a truly normal
population.
Glucose oxidation was not measured because of the signif-
icant additional adsorbed radiation dose to the patient. It is
important to know the effects of DCM and acute stress on
glucose uptake and oxidation to CO2 and release of lactate,
which can only be assessed using [14C]glucose. While the
present study is the first to assess myocardial lactate kinetics in
DCM patients using [13C]lactate tracers, these experiments
would be greatly strengthened by dual-isotopic studies using
[14C]glucose/[13C]lactate tracers, as previously described (9,
39). Another limitation in the metabolic measurements is the
inability to measure the oxidation of intracardiac substrate
stores (e.g., glycogen and triglycerides), which likely played an
important role in supporting the increase in MV˙ O2 in response
to pacing in the DCM group (Fig. 3).
Diabetes was an exclusion criterion for enrolment of both
DCM and control patients; however, it cannot be excluded that
the two patient populations differ in insulin resistance, and that
this could have influenced the metabolic response to stress.
Oral glucose tolerance test was not performed, however, BMI
and the triglycerides/HDL was similar between the two groups,
suggesting that whole body metabolic abnormalities were sim-
ilar.
According to the study protocol, pacing moderately in-
creased heart rate to allow tolerability in DCM patients. This
choice could have caused a relatively lower increase in cardiac
workload in normal hearts than in cardiomyopathic hearts
where the effects of heart rate on energy expenditure are added
to those of enhanced wall stress. Due to the complexity of the
protocol we could not measure ventricular volumes to have a
better estimate of actual workload than that provided by RPP
values. The somewhat artificial conditions of studying these
patients in the catheterization laboratory and the use of heparin
likely resulted in elevated FFA in both groups. Accordingly,
baseline metabolic data should be extended with caution to
what one would see in the unheparized resting state. It would
be best to use a more physiological stimulus to increase MVO2,
such as exercise or high dose dobutamine infusion, however,
these stresses are not feasible in instrumented patients with
DCM prone to arrhythmias.
Conclusions
The present findings demonstrate that DCM patients have a
shift in cardiac metabolism away from FFA oxidation both at
rest and during pacing stress, which is associated with enlarge-
ment of the LV and reduced cardiac work, MVO2, and myo-
cardial blood flow. In addition, these patients show a failure to
further increase glucose uptake and possibly oxidative glyco-
lysis in response to pacing stress. Our results suggest the novel
view that, while the switch away from FFA oxidation in DCM
hearts appears to be compensatory under resting conditions, it
may be detrimental during even moderate stress, potentially
contributing to progressive deterioration of myocardial func-
tion. These findings will better orient therapeutic strategies
aimed at modulating mitochondrial substrate oxidation to re-
duce symptoms and improve cardiac performance in DCM
patients (2, 13).
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